Lorna Tanner helps life sciences companies protect innovation, navigate regulatory challenges and manage portfolios, from their first patent filings to their global intellectual property strategies. She leads the Life Sciences team and serves on the firm's Executive Committee.
Lorna’s work spans patent strategies for therapeutics worldwide, including portfolio management for drugs and biologics. She has been involved in patent strategies for 20 approved drugs and biologics, guiding clients through each stage of product development and launch. Her experience covers patent term extensions, Orange Book listings and pre- and post-grant challenges, helping clients maintain a competitive edge.
With a deep focus on small molecules in clinical development, Lorna also has extensive experience with antibodies, modified proteins and viruses, immunotherapies such as CAR T, biopolymers and advanced drug delivery systems. Her clients range from emerging biopharma companies to global pharmaceutical leaders, and she has prosecuted patent portfolios for groundbreaking therapies, including those licensed to large pharma.
Lorna delivers strategic guidance to clients navigating high-stakes diligence matters, including public offerings, mergers, collaborations and financings. She provides guidance on freedom-to-operate, inventorship and IP risk assessments, helping clients make informed decisions that drive growth and innovation. Her ability to align IP strategy with business goals has earned her recognition as a leading life sciences practitioner.
Beyond her technical expertise, Lorna delivers results. She has successfully represented clients in patent prosecution and counseling, enforcement and licensing matters, helping them secure and defend patents for first-in-class and first-to-market therapies.
